{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:48:35Z","timestamp":1775695715187,"version":"3.50.1"},"publisher-location":"New York, NY","reference-count":25,"publisher":"Springer New York","isbn-type":[{"value":"9781461447252","type":"print"},{"value":"9781461447269","type":"electronic"}],"license":[{"start":{"date-parts":[[2012,12,11]],"date-time":"2012-12-11T00:00:00Z","timestamp":1355184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/978-1-4614-4726-9_12","type":"book-chapter","created":{"date-parts":[[2012,12,10]],"date-time":"2012-12-10T16:04:17Z","timestamp":1355155457000},"page":"151-158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Infectious Risks Associated with Biologics"],"prefix":"10.1007","author":[{"given":"David","family":"Isaacs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,11]]},"reference":[{"key":"12_CR1","unstructured":"FDA Center for Biologics Evaluation and Research (2007\u201310-29) (2011) What are \u201cbiologics\u201d questions and answers. \n                  http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/CBER\/ucm125684.htm\n                  \n                . Accessed 1 Nov 2011 (Last updated 4\/30\/2009)"},{"key":"12_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1136\/adc.2009.170860","volume":"94","author":"MW Beresford","year":"2009","unstructured":"Beresford MW, Baildam EM (2009) New advances in the management of juvenile idiopathic arthritis\u20142: the era of biologicals. Arch Dis Child Educ Pract Ed 94:151\u2013156","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"12_CR3","doi-asserted-by":"crossref","unstructured":"Singh JA, Christensen R, Wells GA et al (2009) Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009(4):CD007848. doi:10.1002\/14651858.CD007848.pub2","DOI":"10.1002\/14651858.CD007848.pub2"},{"key":"12_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0092-8674(01)00237-9","volume":"104","author":"RM Locksley","year":"2001","unstructured":"Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487\u2013501","journal-title":"Cell"},{"key":"12_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/ncb1086","volume":"6","author":"T Bouwmeester","year":"2004","unstructured":"Bouwmeester T, Bauch A, Ruffner H et al (2004) A physical and functional map of the human TNF-alpha\/NF-kappa B signal transduction pathway. Nat Cell Biol 6:97\u2013105 (England)","journal-title":"Nat Cell Biol"},{"key":"12_CR6","doi-asserted-by":"publisher","first-page":"8093","DOI":"10.1073\/pnas.94.15.8093","volume":"94","author":"MW Marino","year":"1997","unstructured":"Marino MW, Dunn A, Grail D et al (1997) Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 94:8093\u20138098","journal-title":"Proc Natl Acad Sci USA"},{"key":"12_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/1074-7613(95)90001-2","volume":"2","author":"J Flynn","year":"1995","unstructured":"Flynn J, Goldstein MM, Chan J et al (1995) Tumor necrosis factor\u2009-\u2009\n\n\n\n\na\n\n\n\n\n is required in the protective immune response against M. tuberculosis in mice. Immunity 2:561\u2013572","journal-title":"Immunity"},{"key":"12_CR8","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/364798a0","volume":"364","author":"J Rothe","year":"1993","unstructured":"Rothe J, Lesslauer W, L\u00f6tscher H et al (1993) Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364:798\u2013802","journal-title":"Nature"},{"key":"12_CR9","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1128\/IAI.69.11.6881-6886.2001","volume":"69","author":"A Wellmer","year":"2001","unstructured":"Wellmer A, Gerber J, Ragheb J et al (2001) Effect of deficiency of tumor necrosis factor alpha or both of its receptors on Streptococcus pneumoniae central nervous system infection and peritonitis. Infect Immun 69:6881\u20136886","journal-title":"Infect Immun"},{"key":"12_CR10","doi-asserted-by":"crossref","unstructured":"Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I (2005) Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev 2005(3):CD005113. doi:10.1002\/14651858.CD005113.pub2","DOI":"10.1002\/14651858.CD005113.pub2"},{"key":"12_CR11","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"EC Keystone","year":"2004","unstructured":"Keystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of treatment with Adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. A randomized, placebo-controlled, 52-week trial. Arth Rheumat 50:1400\u20131411","journal-title":"Arth Rheumat"},{"key":"12_CR12","doi-asserted-by":"crossref","unstructured":"Singh JA, Noorbaloochi S, Singh G (2010) Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010(1):CD008341. doi:10.1002\/14651858.CD008341","DOI":"10.1002\/14651858.CD008341"},{"key":"12_CR13","unstructured":"Food, Drug Administration (2011) FDA: Manufacturers of TNF-blocker drugs must highlight risk of fungal infections. FDA, 2008. \n                  http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2008\/ucm116942.htm\n                  \n                . Accessed 1 Nov 11"},{"key":"12_CR14","unstructured":"Skripak JM, Rodgers GL, Martucci C, Goldsmith DP (2011) Disseminated simplex (HSV) infection precipitating macrophage activation syndrome (MAS) in a child with systemic juvenile idiopathic arthritis (SJIA) undergoing therapy with infliximab. Pediatric Rheumatology Online Journal. #Abstract 58. 2003. Link: http:\/\/www.pedrheumonlinejournal.org\/June\/24.htm. Accessed 1 Jun 2011"},{"key":"12_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/art.24283","volume":"61","author":"Y Komano","year":"2009","unstructured":"Komano Y, Harigai M, Koike R et al (2009) Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum 61:305\u2013312","journal-title":"Arthritis Rheum"},{"key":"12_CR16","unstructured":"Evens AM, Jovanovic BD, Su YC et al (2010) Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol (29 Nov 2010, Epub ahead of print)"},{"key":"12_CR17","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:4834\u20134840","journal-title":"Blood"},{"key":"12_CR18","doi-asserted-by":"crossref","unstructured":"Kean JM, Rao S, Wang M, Garcea RL (2009) Seroepidemiology of human polyomaviruses. PLoS Pathog 5:e1000363. Link: http:\/\/www.plospathogens.org\/article\/info%3Adoi%2F10.1371%2Fjournal.ppat.1000363","DOI":"10.1371\/journal.ppat.1000363"},{"key":"12_CR19","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1086\/597126","volume":"199","author":"A Egli","year":"2009","unstructured":"Egli A, Infanti L, Dumoulin A et al (2009) Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors. J Infect Dis 199:837\u2013846","journal-title":"J Infect Dis"},{"key":"12_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1086\/514062","volume":"176","author":"T Van Der Poll","year":"1997","unstructured":"Van Der Poll T, Keogh CV, Guirao X, Buurman WA, Kopf M, Lowry SF (1997) Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 176:439\u2013444","journal-title":"J Infect Dis"},{"key":"12_CR21","doi-asserted-by":"crossref","unstructured":"Singh JA, Beg S, Lopez-Olivo MA (2010) Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010(7):CD008331. doi:10.1002\/14651858.CD008331.pub2","DOI":"10.1002\/14651858.CD008331.pub2"},{"key":"12_CR22","doi-asserted-by":"crossref","unstructured":"Campbell L, Chen CV, Bhagat SS, Parker RA, Ostor AJK (2010) Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology. doi:10.1093\/rheumatology\/keq343","DOI":"10.1093\/rheumatology\/keq343"},{"key":"12_CR23","doi-asserted-by":"crossref","unstructured":"Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009(1):CD005121. doi:10.1002\/14651858.CD005121.pub3","DOI":"10.1002\/14651858.CD005121.pub3"},{"key":"12_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/00005792-198409000-00001","volume":"63","author":"SC Ross","year":"1984","unstructured":"Ross SC, Densen P (1984) Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine 63:243\u2013273","journal-title":"Medicine"},{"key":"12_CR25","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1634\/theoncologist.2008-0086","volume":"13","author":"A Dmytrijuk","year":"2008","unstructured":"Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R (2008) FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 13:993\u20131000 (Epub 2008 Sep 10)","journal-title":"Oncologist"}],"container-title":["Advances in Experimental Medicine and Biology","Hot Topics in Infection and Immunity in Children IX"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4614-4726-9_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T22:39:04Z","timestamp":1558132744000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4614-4726-9_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,11]]},"ISBN":["9781461447252","9781461447269"],"references-count":25,"URL":"https:\/\/doi.org\/10.1007\/978-1-4614-4726-9_12","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,11]]},"assertion":[{"value":"11 December 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}